Roche Holding AG said an experimental breast-cancer treatment will get an expedited review from US regulators after showing ...
The US Food and Drug Administration (FDA) has granted Roche a breakthrough therapy designation for its breast cancer therapy ...
By Pierre Bertrand Roche said that the U.S. Food and Drug Administration has designated its Inavolisib breast cancer treatment as a breakthrough therapy.
Priority Review recognises the best-in-class potential of the inavolisib-based regimen for patients in urgent need of new treatment options 1,2 Additional analyses of INAVO120 will be presented in ...
(RTTNews) - Swiss drug major Roche Holding AG (RHHBY) and its U.S. Unit Genentech announced Tuesday that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for ...
AstraZeneca and Daiichi Sankyo will discuss with regulators the latest DESTINY-Breast06 data presented at ASCO in the hopes ...
AI tools have impressive potential in personalizing treatments, but doctors are concerned about bias, generalizability, and ...